We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Humana (HUM) Up 5.2% Since the Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Humana Inc. (HUM - Free Report) . Shares have added about 5.2% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock’s next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Humana Beats on Earnings, Misses Revenues in Q4
Humana's fourth-quarter 2016 operating earnings per share of $2.09 beat the Zacks Consensus Estimate of $2.06 roughly by 1.4%. The bottom line also improved 35% year over year due to growth in the individual Medicare Advantage (MA) business as well as higher operating earnings in the Healthcare Services segment.
For 2016, adjusted earnings per share of $9.57 registered 17.6% year-over-year growth.
Operational Update
Revenues inched up 0.8% year over year to $13.46 billion in the fourth quarter due to higher premiums and services revenues. However, the top line missed the Zacks Consensus Estimate by 0.4%. For 2016, the company reported total revenue of $54.96 billion, up 1.2% year over year.
Humana’s consolidated benefit ratio – the percentage of benefit expenses in premium revenues – was 81.2% in the fourth quarter. This is an improvement of 320 basis points (bps) year over year. Consolidated operating cost ratio deteriorated 90 bps year over year to 14.9% due to higher operating cost ratio in both Retail and Group segments.
Quarterly Segment Results
Retail Segment
The segment’s reported premiums and services revenues increased 2% year over year to $11.54 billion due to higher revenues, which in turn, can be attributed to an increase in average membership.
Benefit ratio came in at 83%, up 310 bps from the prior-year quarter. A year-over-year decrease MAutilization and favorable comparisons of Prior Period Development contributed to the result.
Operating cost ratio of 13.1% deteriorated 60 bps year over year due to the higher operating expenses. Adjusted pretax income for the segment was $408 million, up 167% year over year.
Group Segment
Reported premiums and services revenues dipped 2% to $1.82 billion, primarily due to lower medical membership in average fully insured and ASO commercial group.
Benefit ratio improved 120 bps year over year to 82%. This was due to lower utilization as well as favorable development in the fourth quarter. Operating cost ratio deteriorated 220 bps from the prior-year quarter to 26.4%. This was due to unusually low operating expenses in the prior year owing to the temporary suspension of certain discretionary administrative costs.
Adjusted pretax loss for the segment was $13 million, down 150% year over year.
Healthcare Services
Revenues of $6.33 billion increased 6% year over year. The upside was driven by increased mail-order penetration and growth in the company’s individual MA and stand-alone PDP membership.
Operating cost ratio was 95.4%, flat year over year.
Adjusted pretax income for the segment was $278 million, up 9% year over year
Financial Update
As of Dec 31, 2016, cash, cash equivalents, and investment securities of Humana were $13.68 billion, down 16% from the previous quarter. As of Dec 31, 2016, cash and short-term investments of $2.01 billion increased 6% from the previous quarter, primarily due to dividends received from subsidiaries and operating cash derived from the company’s non-insurance subsidiaries’ profits.
As of Dec 31, 2016, debt-to-total capitalization ratio was 27.7%, up 110 bps from the previous quarter.
Cash flows from operations totaled $1.94 billion at the end of 2016 compared with cash flow from operations of $868 million in the prior year.
Share Repurchase and Dividend Update
Humana suspended its share repurchase program on Jul 2, 2015 due to the pending acquisition by Aetna, which has now been blocked by the Justice Department.
Notably, the company’s board of directors approved a new $2 billion share repurchase plan with an expiration date of Dec 31, 2016.
Humana paid cash dividend worth $44 million in the third quarter. For 2016, the total amount paid as dividends to shareholders was $172 million.
How Have Estimates Been Moving Since Then?
Following the release, investors have witnessed an upward trend in fresh estimates. There have been four upward revisions for the current quarter.
At this time, Humana's stock has a nice Growth Score of 'B', however its Momentum is doing a bit better with an 'A'. Following the exact same course, the stock was allocated a grade of 'A' on the value side, putting it in the top 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'A'. If you aren't focused on one strategy, this score is the one you should be interested in.
Zacks' style scores indicate that the company's stock is suitable for value, momentum and growth investors.
Outlook
Estimates have been broadly trending upward for the stock. The magnitude of these revisions also looks promising. Notably, the stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Humana (HUM) Up 5.2% Since the Last Earnings Report?
A month has gone by since the last earnings report for Humana Inc. (HUM - Free Report) . Shares have added about 5.2% in that time frame, outperforming the market.
Will the recent positive trend continue leading up to the stock’s next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Humana Beats on Earnings, Misses Revenues in Q4
Humana's fourth-quarter 2016 operating earnings per share of $2.09 beat the Zacks Consensus Estimate of $2.06 roughly by 1.4%. The bottom line also improved 35% year over year due to growth in the individual Medicare Advantage (MA) business as well as higher operating earnings in the Healthcare Services segment.
For 2016, adjusted earnings per share of $9.57 registered 17.6% year-over-year growth.
Operational Update
Revenues inched up 0.8% year over year to $13.46 billion in the fourth quarter due to higher premiums and services revenues. However, the top line missed the Zacks Consensus Estimate by 0.4%.
For 2016, the company reported total revenue of $54.96 billion, up 1.2% year over year.
Humana’s consolidated benefit ratio – the percentage of benefit expenses in premium revenues – was 81.2% in the fourth quarter. This is an improvement of 320 basis points (bps) year over year. Consolidated operating cost ratio deteriorated 90 bps year over year to 14.9% due to higher operating cost ratio in both Retail and Group segments.
Quarterly Segment Results
Retail Segment
The segment’s reported premiums and services revenues increased 2% year over year to $11.54 billion due to higher revenues, which in turn, can be attributed to an increase in average membership.
Benefit ratio came in at 83%, up 310 bps from the prior-year quarter. A year-over-year decrease MAutilization and favorable comparisons of Prior Period Development contributed to the result.
Operating cost ratio of 13.1% deteriorated 60 bps year over year due to the higher operating expenses.
Adjusted pretax income for the segment was $408 million, up 167% year over year.
Group Segment
Reported premiums and services revenues dipped 2% to $1.82 billion, primarily due to lower medical membership in average fully insured and ASO commercial group.
Benefit ratio improved 120 bps year over year to 82%. This was due to lower utilization as well as favorable development in the fourth quarter.
Operating cost ratio deteriorated 220 bps from the prior-year quarter to 26.4%. This was due to unusually low operating expenses in the prior year owing to the temporary suspension of certain discretionary administrative costs.
Adjusted pretax loss for the segment was $13 million, down 150% year over year.
Healthcare Services
Revenues of $6.33 billion increased 6% year over year. The upside was driven by increased mail-order penetration and growth in the company’s individual MA and stand-alone PDP membership.
Operating cost ratio was 95.4%, flat year over year.
Adjusted pretax income for the segment was $278 million, up 9% year over year
Financial Update
As of Dec 31, 2016, cash, cash equivalents, and investment securities of Humana were $13.68 billion, down 16% from the previous quarter.
As of Dec 31, 2016, cash and short-term investments of $2.01 billion increased 6% from the previous quarter, primarily due to dividends received from subsidiaries and operating cash derived from the company’s non-insurance subsidiaries’ profits.
As of Dec 31, 2016, debt-to-total capitalization ratio was 27.7%, up 110 bps from the previous quarter.
Cash flows from operations totaled $1.94 billion at the end of 2016 compared with cash flow from operations of $868 million in the prior year.
Share Repurchase and Dividend Update
Humana suspended its share repurchase program on Jul 2, 2015 due to the pending acquisition by Aetna, which has now been blocked by the Justice Department.
Notably, the company’s board of directors approved a new $2 billion share repurchase plan with an expiration date of Dec 31, 2016.
Humana paid cash dividend worth $44 million in the third quarter. For 2016, the total amount paid as dividends to shareholders was $172 million.
How Have Estimates Been Moving Since Then?
Following the release, investors have witnessed an upward trend in fresh estimates. There have been four upward revisions for the current quarter.
Humana Inc. Price and Consensus
Humana Inc. Price and Consensus | Humana Inc. Quote
VGM Scores
At this time, Humana's stock has a nice Growth Score of 'B', however its Momentum is doing a bit better with an 'A'. Following the exact same course, the stock was allocated a grade of 'A' on the value side, putting it in the top 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'A'. If you aren't focused on one strategy, this score is the one you should be interested in.
Zacks' style scores indicate that the company's stock is suitable for value, momentum and growth investors.
Outlook
Estimates have been broadly trending upward for the stock. The magnitude of these revisions also looks promising. Notably, the stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.